Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70420 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Kee Huat Chuah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Diet, Carbohydrate-Restricted, Gastrointestinal Agents, Irritable Bowel Syndrome, Rifamycins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: UMSC C.A.R.E Research Grant.
Abstract (Originalsprache)
Background
Rifaximin and the low FODMAP diet (LFD) are suggested as second‐line therapies for irritable bowel syndrome (IBS). Direct comparative data are limited.
Aims
To compare the efficacy of rifaximin and LFD in IBS.
Methods
In this single‐blind, randomised controlled trial, we allocated adults with IBS to rifaximin or LFD. The primary outcome was composite symptom improvement (abdominal pain/discomfort and stool consistency/frequency) at Week 4. Secondary outcomes included individual symptom improvement, ≥ 50 point reduction in IBS Symptom Severity Scale (IBS‐SSS), health‐related quality of life (HRQOL), Hospital Anxiety and Depression Scale (HADS), small intestinal bacterial overgrowth (SIBO) eradication, adherence and adverse events.
Results
We randomised 100 patients equally (median age 50 years; 52% female; 68% IBS‐D; 17% SIBO). Based on the composite symptom assessment, response rates were similar between groups (rifaximin 56.0% vs. LFD 48.0%, p = 0.423) at Week 4. However, rifaximin led to significantly earlier individual symptom improvement at Week 2, including global symptoms (90.0% vs. 72.0%, p = 0.022), bloating (84.0% vs. 58.0%, p = 0.004) and abdominal pain (80.0% vs. 58.0%, p = 0.017). HRQOL and anxiety scores improved in both groups. SIBO eradication was observed in 63.6% (rifaximin) and 50.0% (LFD). Adherence was significantly better with rifaximin (95.9% vs. 77.8%, p = 0.008). No serious adverse events occurred.
Conclusion
Rifaximin is as effective as LFD in treating IBS over 4 weeks. However, it provides faster symptom relief and higher treatment adherence, making it a practical alternative for symptom management. Trial Registration ClinicalTrials.gov: NCT number: NCT04841980
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- Staff & Student Health Unit, Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia.
- Centre for Population Health (CePH), Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- School of Health Rehabilitation Sciences, Health Sciences University, Bournemouth, UK.
ORCID-Profile: Kee Huat Chuah, Sanjiv Mahadeva
Förderung
- UMSC C.A.R.E Research Grant
Zitieren
APA
Chuah, K. H., Loo, Q. Y., Loh, A. J. C., Leong, J. Y., Chan, W. L., Khoo, X. H., Wong, K. L., Panirsheeluam, S., Natarajan, V., Ng, A. K., Abdul Majid, H., & Mahadeva, S. (2026). Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70420
Vancouver
Chuah KH, Loo QY, Loh AJC, Leong JY, Chan WL, Khoo XH, et al. Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70420
BibTeX
@article{Chuah2026,
author = {Chuah, Kee Huat and Loo, Qing Yuan and Loh, Audrey Joe Chii and Leong, Jing Yi and Chan, Wah Loong and Khoo, Xin Hui and Wong, Kim Leng and Panirsheeluam, Sarala and Natarajan, Vicraman and Ng, Ai Kah and Abdul Majid, Hazreen and Mahadeva, Sanjiv},
title = {Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70420}
}
EUVIMED